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Abstract
Antipsychotic polypharmacy (APP), which is common in adults with psychotic disorders, is of
unproven efficacy and raises safety concerns. Although youth are increasingly prescribed
antipsychotics, little is known about APP in this population. We performed a systematic PubMed
search (last update 26 January 2013) of studies reporting the prevalence of APP in antipsychotic-
treated youth. Summary statistics and statistical tests were calculated at the study level and not
weighted by sample size. Fifteen studies (n=58 041, range 68–23 183) reported on APP in youth
[mean age=13.4±1.7 yr, 67.1±10.2% male, 77.9±27.4% treated with second-generation
antipsychotics (SGAs)]. Data collected in these studies covered 1993–2008. The most common
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diagnoses were attention-deficit hyperactivity disorder (ADHD; 39.9±23.5%) and conduct
disorder/oppositional defiant disorder (CD/ODD; 33.6±24.8). In studies including predominantly
children (mean age=<13 yr, N=5), the most common diagnosis were ADHD (50.6±25.4%) and
CD/ODD (39.5±27.5%); while in studies with predominantly adolescents (mean age =≥13 yr,
N=7) the most common diagnoses were schizophrenia-spectrum disorders (28.6±23.8%), anxiety
disorders (26.9±14.9%) and bipolar-spectrum disorders (26.6±7.0%), followed closely by
CD/ODD (25.8±17.7). The prevalence of APP among antipsychotic-treated youth was 9.6±7.2%
(5.9±4.5% in child studies, 12.0±7.9% in adolescent studies, p=0.15). Higher prevalence of APP
was correlated with a bipolar disorder or schizophrenia diagnosis (p=0.019) and APP involving
SGA+SGA combinations (p=0.0027). No correlation was found with APP definition [≥1 d (N=10)
vs. >30–≥90 d (N=5), p=0.88]. Despite lacking safety and efficacy data, APP in youth is not
uncommon, even in samples predominantly consisting of non-psychotic patients. The duration,
clinical motivations and effectiveness of this practice require further study.
Keywords
Adolescents; antipsychotics; attention deficit-hyperactivity disorder; children; combination;
disruptive behaviour disorders; paediatric; polypharmacy
Introduction
Psychotropic medication polypharmacy is common in the treatment of psychiatric disorders
(Faries et al. 2005). Among different combinations, antipsychotic polypharmacy (APP) has
received the most attention. Especially controversial is the fact that a fairly large number of
patients with schizophrenia-spectrum disorders receive APP, despite lack of sound evidence
for its efficacy (Correll et al. 2009a; Goodwin et al. 2009) and concerns about increased
acute and long-term adverse effect burden and cost (Gallego et al. 2012a,b). In adult
psychiatric populations, 7–50% of antipsychotic-treated patients receive APP, with
variations in patient population characteristics, setting and APP definition (Faries et al.
2005; Ganguly et al. 2004; Kreyenbuhl et al. 2006). In a recent systematic review of APP
across 147 studies and 1 418 163 adults (82.9% with a diagnosis of schizophrenia), the
median prevalence across cultures and four decades was 19.6% (Gallego et al. 2012a).
In adults, APP has been associated with several patient, illness treatment and environmental
factors (Correll & Gallego 2012). Potential reasons for APP include a diagnosis of
schizophrenia (Messer et al. 2006), greater illness severity, longer illness duration and
increased hospitalization rates and duration (Centorrino et al. 2004; Gilmer et al. 2007).
Potential consequences of APP include greater adverse effect burden (Gallego et al. 2012b;
Jerrell & McIntyre, 2008; McIntyre & Jerrell, 2008), higher total antipsychotic doses
(Bingefors et al. 2003; Elie et al. 2009; Hung & Cheung, 2008) and treatment cost (Rupnow
et al. 2007; Stahl & Grady, 2006). In adults, APP is used in an effort to enhance or
accelerate antipsychotic efficacy, treat symptoms other than psychosis (Pandurangi &
Dalkilic, 2008) or reduce the dose of the first antipsychotic without loss of overall efficacy
(Correll & Gallego, 2012). APP also commonly occurs during antipsychotic cross-titration
and after an aborted antipsychotic switch (Stahl & Grady, 2004).
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As in adults, there has been a substantial increase in the use of antipsychotics,
predominantly atypical or second-generation antipsychotics (SGAs) among children and
adolescents (Olfson et al. 2006, 2012). In this age group, antipsychotics are prescribed for a
variety of mental disorders, including psychotic, affective, impulse-control, externalizing
behavioural and tic disorders (Correll et al. 2011; Olfson et al. 2006, 2012). Although APP
may be lower in specific populations, such as patients with a first psychotic episode (Castro-
Fornieles et al. 2008), APP rates have been rising in such populations as well (Nielsen et al.
2010a,b).
Despite mounting evidence for the efficacy of antipsychotics in paediatric populations
(Fraguas et al. 2011; Zuddas et al. 2011), concerns exist over increasing antipsychotic use
by youth, including the fact that clinical indications for the prescription of antipsychotics are
not always clear. In particular, high prescription rates for aggressive spectrum disorders,
coupled with potential under-utilization of non-pharmacological treatments have called into
question the use of one, let alone, two concurrently prescribed antipsychotics (Crystal et al.
2009). Moreover, paediatric patients are generally more sensitive to medication adverse
effects (Correll, 2008). Even short-term exposure to single antipsychotic treatment can cause
dramatic weight gain and metabolic abnormalities (Correll et al. 2009b). Because increased
adverse effects have clearly been associated with APP in adults (Gallego et al. 2012b), there
is concern that APP may also increase the risk of adverse effects in the vulnerable paediatric
population.
Scant research has focused on prevalence and predictors of combined antipsychotic use in
children and adolescents. Therefore, we aimed to systematically review APP prevalence and
correlates in the paediatric psychiatric population.
Method
Data sources
An electronic search was carried out on 10 February 2012, updated on 3 July 2012 and 26
January 2013, in PubMed since inception of the data base without language restriction, using
the following search terms: (antipsychotic OR antipsychotics) AND (child OR children OR
childhood OR adolescent OR adolescents OR adolescence OR pediatric) AND (concomitant
OR polypharmacy OR co-prescription OR co-treatment OR combination). Reference lists
from retrieved articles were used to further identify additional studies and authors were
contacted to provide additional data as necessary.
Study selection
All studies that reported quantitative estimates of APP in antipsychotic-treated children or
adolescents were included in the review. We employed a broad working definition of APP
as the concurrent use of two or more antipsychotics as reported in each study. This included
either at least 1 d of antipsychotic overlap or a required minimal period of combined
antipsychotic treatment as per study definition. Whenever possible, studies that combined
adult and paediatric populations were included if they allowed separate extraction of data
regarding APP in children and adolescents. Similarly, studies that included patients without
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antipsychotic treatment in the denominator were included if APP prevalence among
antipsychotic-treated patients could be calculated.
Data extraction
Data were extracted by two authors (N.T., J.A.G.) and checked by a third (C.U.C.) using the
following categories: author; year of publication of the study; country of origin and country
of data collection; number of patients included in the study; setting of the study (in-patient
vs. out-patient vs. mixed); location of the study (urban vs. rural); setting in which the study
was conducted (teaching hospital vs. other); time of data collection. Mean age of the sample
and racial information (% white) were also extracted. To further characterize APP, we
recorded the definition of polypharmacy from each study, reported APP proportions among
subjects receiving antipsychotics and the type of psychiatric co-medications and
antipsychotic class combinations [SGA+first-generation antipsychotic (FGA) or (SGA
+SGA)].
Statistical method
All analyses were calculated at the study level and not weighted by sample size. Mean and
standard deviations for normally distributed data were calculated from the pooled data.
Mean age was extracted or calculated for each study and, when data were available (N=11),
studies were assigned to one of two groups based on the mean age of the entire study
sample, i.e. ≥13.0 (predominantly ‘adolescents’) or <13.0 (predominantly ‘children’). Age
groups were assigned in order to compare APP in predominantly pre-pubertal and
predominantly post-pubertal patients. To compare potential time trends, studies were
categorized by data collection period into studies conducted in the 1990s or 2000s. In three
studies where the data collection time spanned both decades, studies were assigned to one of
the two decades based on the median time of the data collection period. Pearson’s χ2 test
was used to compare categorical data and t test was used to compare continuous data
between the two groups. Correlates of APP were analysed with bivariate analyses, using
Pearson’s correlation coefficient. Data were analysed using JMP 5.0.1, 1989–2003, SAS
Institute Inc. and STATA version 11 (Stata Corp, USA); all tests were two-sided, and α was
set at 0.05.
Results
Search
The literature search identified 1405 articles. Of these, 1358 non-relevant articles were
excluded based on the title and the abstract. Of 47 full text articles, 32 were excluded
because they either reported on the prevalence of APP in adults, the prevalence of non-APP
in children and adolescents or were review articles, yielding 15 studies for the final analyses.
Study characteristics
In the 15 studies (sample size range 68–21 183) APP was examined in a total of 58 041
patients (Table 1). Of the 11 studies with period data, two (18.2%) were conducted entirely
in the 1990s, six (54.6%) entirely in the 2000s and three studies (27.3%) included
assessments in both the 1990s and 2000s and were assigned to the study decade based on the
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median data collection period. There were five studies (n=21 581) conducted predominantly
in children, seven studies (n=746) conducted predominantly in adolescents and three studies
with mixed child and adolescent samples without providing a mean age (n=35 714). Most
studies were performed in urban settings (58.3%), at university/teaching hospitals (58.3%),
in out-patients and mixed settings (53.4%) and in the US (80.0%; Table 2).
Ten studies (75.0%) used the broadest definition of APP, requiring ≥1 d of antipsychotic co-
treatments and five studies (25.0%) required antipsychotic co-treatment to last for >30 d
(Morrato et al. 2007), ≥60 d (Constantine et al. 2010; dosReis et al. 2011; Hong & Bishop,
2010) or ≥90 d (Kogut et al. 2005). Moreover, two studies restricted the definition of APP to
either a combination of risperidone with another antipsychotic (Simeon et al. 2002), or to a
combination of FGA+SGA (Wonodi et al. 2007).
Studies including samples with a mean age=<13.0 yr (‘child’ group) did not differ from
those with a mean age=≥13.0 (‘adolescent’ group) regarding any study characteristics
besides age, except that six of seven studies (85.7%) in the adolescent groups included only
in-patients compared to none in the child studies (p=0.0034; Table 2).
Subject characteristics
The mean patient age in the studies was 13.4±1.7 yr (N=12), 67.1±10.2% were male (N=13)
and 56.9±22.4% (N=10) were white. The mean patient age in studies assigned to the child
group was 11.6±0.9 yr (N=5) and 14.6±0.7 yr (N=7; p=0.0004) in the adolescent group. No
significant differences in sex and race were present between the predominantly child and
adolescent studies (Table 2).
The most commonly reported diagnoses were attention-deficit hyperactivity disorder
(ADHD; 39.1±26.2%), followed by conduct disorder (CD) or oppositional defiant disorder
(ODD; 31.5±22.3%). The most common diagnosis in the child studies was ADHD
(50.6±25.4%), followed by CD/ODD (39.5±27.5%); whereas the most common diagnoses
in the adolescent studies were schizophrenia-spectrum disorders (28.6±23.8), anxiety
disorders (26.9±14.9) and bipolar-spectrum disorders (26.6±17.2), followed closely by
CD/ODD (25.8±17.7; Table 2).
Psychotropic medication prescribing patterns
Among the study samples, the most commonly prescribed antipsychotics were SGAs
(77.9±27.4%). The FGA proportion was 14.5±17.2% (N=7) in the entire sample and
3.6±2.9% (N=2) in the child group vs. 18.9±19.0% (N=5) in the adolescent group (p=0.33;
Table 3). While the prevalence of SGA prescribing did not differ in studies conducted in the
1990s (77.5±23.3%) or 2000s (76.8±36.3%, p=0.96), FGAs accounted for a smaller
percentage in the studies conducted in the 2000s than in the earlier period (5.4±5.2% vs.
37.2±15.3%, p=0.0060). The mean proportion of subjects receiving clozapine (0.6±0.8%)
and long-acting, injectable antipsychotics (0.1%) was very low (Table 3).
The mean reported prevalence of APP was 9.6±7.2%. This estimate was consistent (p=0.89)
across studies with a broad APP definition [i.e. ≥1 d of antipsychotic co-treatment (N=10):
9.8±7.8%] and those with a more conservative definition [i.e. requiring a minimum of 1–3
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months of combined antipsychotic use (N=5): (9.2±6.5%)]. The APP prevalence was
7.2±4.7% in studies conducted in the 1990s (N=5) and 9.8±7.8% in those conducted in the
2000s (N=9; p=0.51).
The most common antipsychotic class combination was FGA+SGA (70.9±44.1%) followed
by SGA+SGA (30.2±45.5%). FGA+FGA combinations were absent in the nine studies with
data. Across the two decades, the proportion of FGA+SGA combinations (100±0% vs.
53.0±54.5%, p=0.14) did not differ significantly.
Antidepressants (38.1±18.3%) and mood stabilizers (37.4±24.8%) were the most commonly
prescribed co-medications, followed by psychostimulants (31.5±26.0%), anxiolytics/
hypnotics (17.0±18.9%) and anticholinergics (13.8±9.5%) (Table 3).
Psychotropic medication prescribing characteristics by predominant age group (children
vs. adolescents)
The mean APP prevalence was numerically lower in children (5.9±4.5%) than in
adolescents (12.0±7.9%, p=0.15; Table 3). The mean APP prevalence for the predominantly
child sample was 6.1±4.6% (N=2) in the 1990s and 5.9±5.5% (N=3) in the 2000s (p=0.97).
By contrast, the mean APP prevalence in predominantly adolescent samples rose non-
significantly from 7.9±5.6% (N=3) in the 1990s to 15.1±8.6% (N=4) in the 2000s (p=0.27).
Similarly, statistically non-significant differences were observed between predominantly
child and adolescent samples regarding antipsychotic class combinations. FGA+SGA
combinations were commonly prescribed in both child and adolescent samples (100% vs.
62.4±51.7%, p=0.27), whereas SGA+SGA combinations were not described in child, but
only in adolescent samples (0.0±0.0% vs. 37.6±51.7%, p=0.27; Table 3).
In the child samples, stimulants were most commonly co-prescribed with antipsychotics
(51.9±25%), significantly more than in adolescent samples (14.6±9.1%, p=0.0076),
followed by antidepressants (47.8±22.0%). By contrast, in the adolescent samples, mood
stabilizers were the most frequent co-medication class (40.8±21.7%), also followed by
antidepressants (32.6±14.7%; Table 3).
Correlates of APP
Bivariate ecological comparisons at the study level revealed a significant positive correlation
between increasing APP prevalence and larger proportions of subjects with a diagnosis of
bipolar- or schizophrenia-spectrum disorders (r2=0.08, p=0.019), co-treatment with
anxiolytics/hypnotics (r2=0.08, p=0.869), as well as SGA+SGA combinations (r2=0.746,
p=0.0027). Correspondingly, FGA+SGA combinations showed a significant negative
correlation with APP prevalence (r2=0.738, p=0.0030). No other variables were significantly
correlated with APP (Table 4).
Discussion
In this systematic review of APP patterns in youth, the average APP prevalence in child and
adolescent studies was 9.6±7.2%. The prevalence among child studies (5.9±4.5%) was
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numerically lower than among adolescent studies (12.0±7.9%), but the small number of
studies limited formal inferences. The average APP prevalence estimates in youth studies in
the 1990s (7.2%) and 2000s (9.8%) were lower than the respective estimates of 22.0 and
19.2% in these decades in a systematic review of APP prevalence in adults (Gallego et al.
2012a). This lower APP prevalence in youth is consistent with a much lower prevalence of
psychotic disorders in antipsychotic-treated paediatric studies (22.27%) compared to adult
studies (82.9%) and a significant positive correlation in the paediatric samples between APP
and a diagnosis of a bipolar- or schizophrenia-spectrum disorder. In a meta-regression of
147 studies and 1 418 163 adult patients, APP was also associated with a schizophrenia
diagnosis, in addition to in-patient status and FGA use (R2=0.44, p<0.0001; Gallego et al.
2012a). While the APP prevalence remained stable across the two decades of investigation
in the child studies (i.e. 6.1 and 5.9%), the APP prevalence in predominantly adolescent
studies almost doubled from 7.9% in the 1990s to 15.1% in the 2000s. This is a potentially
concerning trend that needs to be examined further, given that our findings were based on a
relatively small number of studies.
In recent years, the perceived efficacy, safety, ease of use and tolerability of SGAs has led to
their increasing utilization in the treatment of non-psychotic symptoms and disorders in
children and adolescents (Olfson et al. 2006, 2012). In recent years, five SGAs (aripiprazole,
olanzapine, paliperidone, quetiapine, risperidone) have received FDA approval for use in
children and adolescents with schizophrenia, four have been approved for paediatric bipolar
mania and two for use in autistic youth with significant irritability (Correll et al. 2011). In
the studies reporting on APP, most patients were prescribed SGAs (77.9%). Prescription
rates for FGAs were far lower (14.5%) in the overall sample, in predominantly adolescent
samples (18.9%) and, particularly, in predominantly child samples (3.6%). However, FGAs
were prescribed significantly more commonly in the one study reporting on antipsychotic
class prescribing in the 1990s (37.2%) than in studies conducted in the 2000s (5.4%). This
strong shift to SGAs in youth in the 2000s is in contrast to FGA prescription rates reported
in adults in the 1990s (53.0%) and 2000s (40.5%; Gallego et al. 2012a). Similar results were
found in a recent study from the US, which analysed out-patient visits to physicians in
office-based practices from the 1993–2009 National Ambulatory Medical Care Surveys
(N=484 889). In this study, FGAs also represented a greater proportion of adult (11.9%) than
adolescent (1.8%) or child (1.3%) antipsychotic medications (Olfson et al. 2012). Thus, in
youth, clinicians use FGAs much more sparingly, which is likely related to the high risk for
acute extra pyramidal side-effects (EPS; Correll, 2008) and the significantly lower long-term
risk of SGAs for tardive dyskinesia in adults (Correll et al. 2004) and youth (Correll et al.
2007).
Similar to adult studies (Kreyenbuhl et al. 2007; McCue et al. 2003), we found that the most
common antipsychotic class combination consisted of FGA+SGA (70.9%). Subgroup
analyses revealed that all three child studies with data on antipsychotic class combinations
reported only FGA+SGA combinations. This combination was also more commonly
prescribed in adolescent studies (62.4%), but 37.6% of combinations included SGAs only.
This overall finding is in contrast to a previous study, in which 89% of the days of APP in
the 6–12 yr age group and 73% of the days of APP in adolescents involved combinations of
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SGAs (Constantine et al. 2010). However, this study reported data from 2002 to 2007, when
SGAs were generally more widely prescribed.
Although APP consisted mostly of SGA+FGA combinations, higher use of SGA+SGA and
lower proportions of FGA+SGA combinations were associated with increased overall APP
prevalence. This is consistent with the aforementioned lower EPS rates with SGAs than
FGAs, which are therefore more readily combined, especially in children and adolescents
who are particularly sensitive to EPS (Correll, 2008). Nevertheless, the extent of FGA+SGA
combinations as well as the lack of difference between APP prevalence in studies using a
broad definition of APP (i.e. at least 1 d of antipsychotic co-treatment) compared to studies
that required at least 30, 60 or 90 d of combined antipsychotic use suggests substantial
proportions of deliberate antipsychotic co-treatment, rather than overlapping antipsychotic
use during switching. In adult studies, however, definitions of APP requiring longer periods
of antipsychotic co-prescribing were associated with lower APP prevalence (Gallego et al.
2012a). Future studies should report on APP using varying thresholds of required APP
duration to determine the true prevalence of long-term APP.
Although a strong association between schizophrenia and APP has been demonstrated in
adults (Biancosino et al. 2006; Castberg & Spigset 2008; Fourrier et al. 2000; Morrato et al.
2007) and in two paediatric studies (Constantine et al. 2010; dosReis et al. 2011),
schizophrenia-spectrum disorders were not correlated with APP in the overall reviewed
database. This may be a problem of sample size or related to the different indications of use
of APP in younger populations. One study of 16 969 foster youth with mean age of 12.8 yr
included in our review (dosReis et al. 2011) showed that youngsters were more likely to be
prescribed concomitant antipsychotics if they had a diagnosis of CD (odds ratio 1.43,
p<0.001). In our overall analyses, however, we did not find a significant correlation between
individual diagnoses and APP. Nevertheless, the high prescribing rates of antipsychotics for
youth with ODD and CD, or even ADHD (Olfson et al. 2012), are clearly of concern, as no
FDA approval exists and other, non-pharmacological treatments should be used first
(Scotto-Rosato et al. 2012). Combining bipolar-with schizophrenia-spectrum disorders
revealed a correlation with APP (p=0.019). Unlike adult studies (Correll & Gallego, 2012),
we found no significant correlation between APP and male sex, use of clozapine or long-
acting injectables, prescription of any other co-medications, including anticholinergics or
lower antidepressant rates in the paediatric samples included in this review. However, there
was a significant correlation between greater use of anxiolytics/hypnotics and APP in youth
(p=0.0067). To date, it is unclear what this correlation is due to, but it is possible that
benzodiazepines as well as a second antipsychotic are used in an attempt at targeting
agitation and aggression in seriously ill youth.
The results of this study have to be interpreted within its limitations. First, the number of
studies reporting on APP in youth was limited and study sizes and clinical settings varied
widely. Second, APP definitions varied between studies. Two studies limited the APP
definition to specific agents (risperidone+AP and FGA+SGA, respectively), likely resulting
in an underestimation of the true APP prevalence. In addition, the broad definition of APP in
10 of the 15 studies that included at least APP day does not permit distinguishing short-term
overlap of antipsychotic treatment during cross-titration from intended longer-term APP.
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However, APP consisted predominantly of FGA+SGA combinations. Since FGA
monotherapy has become rather uncommon in youth, the FGA-SGA combination is most
likely part of longer-term APP. The fact that the proportion of FGA-SGA combination did
not differ between the 1990s, where switching from FGAs to SGAs would have been more
common, strengthens the argument that FGA+SGA combinations may in fact be part of
intended longer-term APP use. Third, we did not have data on prior treatment attempts and
failures or other data that could have provided clues to the reasons for, and the risks and
benefits of, the implemented APP. In this context, the limited data did not allow us to
confirm clozapine that was prescribed to only 0.6% of youth across five studies with data
was underutilized in patients with schizophrenia-spectrum disorders. Similarly, we could not
assess if APP was used instead of more appropriate and evidence-based use clozapine in
youth with refractory schizophrenia (Schimmelmann et al. 2013), as has been suggested in
adults (Nielsen et al. 2010a,b). Fourth, as with any review and pooled analysis, combining
data from studies that were conducted using different methodologies, at different time-
points, in different countries and patient populations makes a direct comparison of studies
difficult. Finally, all comparisons were ecological on the level of study data and did not
allow inferences on the level of individual patients. Nevertheless, to our knowledge, this is
the first review that focuses on the prevalence and correlates of APP in children and
adolescents and our analyses provide initial data that should be followed up further.
In summary, this review suggests that APP is not uncommon in children and adolescents.
The average APP prevalence from 15 studies suggests that about one in 10–11 youth who
receive an antipsychotic medication receive APP. This proportion was observed in studies
using broad and more restricted definitions of APP. In adolescent samples studied in the
2000s, the mean prevalence was even higher, implicating one in eight youth. This practice is
of concern, as its benefits are unclear and its long-term safety is not well established. Further
research is needed to better understand the reasons for and correlates of short-term and
sustained APP in youth and to identify its potential risk and benefits in the vulnerable
paediatric population, especially for young people with non-psychotic disorders.
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Table 2
Study and patient characteristics
Total samplea
N=58 041
Predominantly
child studiesb
n = 21 581
Predominantly
adolescent studiesc
N=746 p value
Study characteristics
 Number of studies 15 a 5 7
Study period (N,%) 0.92
 Median <2000 5 (35.7%) 2 (40.0%) 3 (42.7%)
 Median ≥2000 9 (64.3%) 3 (60.0%) 4 (57.1%)
Location (N,%) 0.49
 Urban 7 (58.3%) 3 (60.0%) 4 (80.0%)
 Mixed (urban and rural) 5 (41.7%) 2 (40.0%) 1 (20.0%)
Institution type (N,%) 0.34
 University-teaching institutions 7 (58.3%) 2 (50.0%) 4 (80.0%)
 Non-university/mixed institutions 5 (41.7%) 2 (50.0%) 1 (20.0%)
Setting (N,%) (13) (5) (7) 0.0034
 In-patient 6 (46.2%) 0 (0%) 6 (85.7%)
 Out-patient and mixedd 7 (53.4%) 5 (100.0%) 1 (14.3%)
Country (N,%) (15) (5) (7) 0.24
 United States 12 (80.0%) 4 (80%) 5 (71.5%)
 Europe 2 (13.3%) 0 (0%) 2 (28.6%)
 Australia 1 (6.7%) 1 (20%) 0 (0%)
Patient characteristics
Demographics
 Age (mean, S.D.) 13.4±1.7 (12) 11.6±0.9 (5) 14.6±0.7 (7) 0.0004
 White (N,%) 56.9±22.4 (10) 54.5±18.2 (2) 59.1±25.9 (7) 0.82
 Male (N,%) 67.1±10.2 (13) 68.3±11.0 (5) 66.0±11.2 (7) 0.73
Diagnosis (N,%)
 ADHD 39.1±26.2 (8) 50.6±25.4 (5) 13.1±14.0 (2) 0.12
 CD or ODD 31.5±22.3 (8) 39.5±27.5 (4) 25.8±17.7 (3) 0.49
 Bipolar spectrum disorders 24.6±15.1 (8) 20.8 (1) 26.6±17.2 (6) 0.77
SCZ-spectrum disorders 22.2±20.1 (13) 16.4±13.8 (5) 28.6±23.8 (7) 0.33
Anxiety disorders/depressive disorders 18.7±12.7 (7) 14.6±8.0 (3) 26.9±14.9 (3) 0.27
Pervasive developmental disorders 18.3±10.8 8) 18.8±21.3 (2) 20.8±6.15) 0.83
14.2±10.2 (7) 16.7±10.4 (3) 12.3±11.2 (4) 0.62
ADHD, Attention deficit-hyperactivity disorder; CD, conduct disorder; ODD, oppositional defiant disorder; SCZ, schizophrenia.
Values shown in bold indicate significant p values.
aNot all studies contributed data to all categories and the total number of studies is larger than the sum of child and adolescent studies, as data for
mean age were not available in two studies.
bStudies in which the mean participant age was <13.0 yr.
cStudies in which the mean participant age was ≥13.0 yr.
Int J Neuropsychopharmacol. Author manuscript; available in PMC 2014 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Toteja et al. Page 16
d
Four studies contained mixed samples, predominantly consisting of out-patients, and 3 studies contained exclusively outpatients; Number of
studies contributing data is shown in parentheses.
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Table 3
Psychotropic medication prescribing practices in the total sample and in subsamples consisting predominantly
of children vs. adolescents
Treatment characteristics
Total no. of
studies with
dataa
Total sample
N=15a
Predominantly
child studiesb
n=21 581
Predominantly
adolescent studiesc
N=636
p
valued
Antipsychotics
 1 antipsychotic 13 81.4±14.1 75.8±16.5 (4) 80.9±13.5 (7) 0.59
 2 antipsychotics 10 11.6±11.5 4.5±1.6 (3) 16.4±13.1 (6) 0.17
 3 or more antipsychotics 8 0.01±0.01 0.01±0.02 (3) 0.0±0.0 (5) 0.22
 APP (≥2 antipsychotics)e 15 9.6±7.2 5.9±4.5 (5) 12.0±7.9 (7) 0.15
 FGA 7 14.5±17.2 3.6±2.9 (2) 18.9±19.0 (5) 0.33
 SGA 11 77.9±27.4 70.0±40.7 (4) 82.4±18.9(7) 0.50
 Clozapine 5 0.6±0.8 0.4 (1) 0.7±1.2 (3) 0.85
 Long-acting injectable
antipsychotics 1 0.1 0.1 (1) − (0) NA
APP (≥2 antipsychotics) pattern
 FGA+FGA 9 0.0±0.0 0.0±0.0 (3) 0.0±0.0 (5) NA
 SGA+SGA 9 30.2±45.5 0.0±0.0 (3) 37.6±51.7 (5) 0.27
 FGA+SGA 9 70.9±44.1 100±0.0 (3) 62.4±51.7 (5) 0.27
Co-medications
 Antidepressants 11 38.1±18.3 47.8±22.0 (4) 32.6±14.7 (7) 0.20
 Mood stabilizersf 12 37.4±24.8 32.7±30.7 (5) 40.8±21.7 (7) 0.60
 Stimulants 11 31.5±26.0 51.9±25.0 (5) 14.6±9.1 (6) 0.0076
 Anxiolytics/hypnotics 6 17.0±18.9 3.4±3.3(2) 23.8±20.2 4) 0.25
 Anticholinergics 6 13.8±9.5 1.0 (1) 16.4±8.0 (5) 0.15
APP, Antipsychotic polypharmacy; FGA, first-generation antipsychotic; SGA, second-generation antipsychotic.
Values shown in bold indicate significant p values.
aNot all studies contributed data to all categories and the total number of studies is larger than the sum of child and adolescent studies, as data for
mean age were not available in two studies.
bStudies in which the mean participant age was <13.0 yr.
cStudies in which the mean participant age was ≥13.0 yr.
d
t test.
e
The APP prevalence is not identical to the sum of patients taking 2 or ≥3 antipsychotics, as not all studies reporting on APP specified the exact
number of antipsychotics prescribed.
f
The terms ‘mood stabilizers’ consists of ‘mood stabilizers’ and ‘anticonvulsants’ plus ‘lithium’ as reported in the publications.
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Table 4
Correlates of antipsychotic polypharmacy
Variables
No. of
studies r 2
p
value
Demographics
Mean age 12 0.090 0.34
% White 10 0.022 0.68
% Male 13 0.038* 0.52
Diagnoses
 % Psychotic disorders 13 0.10 0.29
 % Bipolar spectrum
disorders
8 0.225 0.24
 % Bipolar or schizophrenia
spectrum disorders
13 0.408 0.019
 % Depressive disorders 8 0.070 0.53
 % Anxiety disorders 7 0.328 0.18
 % ADHD 8 0.175 0.30
 % Pervasive developmental
 disorders
7 0.116 0.45
 % ODD/Conduct disorders 8 0.258 0.20
Treatment
 % FGA 7 0.001 0.94
 % SGA 11 0.133 0.27
 % Clozapine 5 0.001 0.97
 % Decanoate preparations 1 NA NA
 % Mood stabilizers 12 0.014 0.72
 % Anxiolytics/hypnotics 6 0.869 0.0067
 % Antidepressants 11 0.001 0.94
 % Stimulants 11 0.002 0.89
 % Anticholinergics 6 0.005 0.90
 % SGA+SGA 9 0.746 0.0027
 % FGA+SGA 9 0.738 * 0.0030
ADHD, Attention deficit-hyperactivity disorder; FGA, first-generation antipsychotic; ODD, oppositional defiant disorder; SGA, second-generation
antipsychotic.
Values shown in bold indicate significant p values.
*Negative correlation.
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